Trial
NCT01917006
A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Allergan
Collaborators
—
Condition
Premature Ejaculation
Intervention
OnabotulinumtoxinA
Why stopped
Strategic business decision was made to terminate the program. There were no safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-10-18